Profile data is unavailable for this security.
About the company
North China Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production and sales of pharmaceutical products. The Company's main products include anti-infective drugs, nephrology and immunomodulatory drugs, biotechnology drugs, cardiovascular and cerebrovascular and immunomodulatory agents, vitamins and health consumer products, nervous and blood system drugs, pharmaceutical intermediates, anti-epidemic drugs, pesticides and Veterinary drugs. The Company is also engaged in pharmaceutical and other logistics trade pharmaceuticals. The Company's products are mainly used in chemical pharmaceuticals, modern biotechnology drugs, vitamins and health consumer products, bioagricultural and veterinary drugs and other fields. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)9.79bn
- Net income in CNY183.03m
- Incorporated1992
- Employees10.09k
- LocationNorth China Pharmaceutical Co LtdNo. 388, Heping East RoadSHIJIAZHUANG 050015ChinaCHN
- Phone+86 31 187173756
- Fax+86 31 186060942
- Websitehttp://www.ncpc.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harbin Pharmaceutical Group Co Ltd | 15.94bn | 449.15m | 8.69bn | 9.85k | 19.35 | 1.54 | -- | 0.5451 | 0.1783 | 0.1783 | 6.33 | 2.25 | 1.12 | 5.90 | 3.34 | -- | 3.42 | 1.58 | 8.28 | 4.28 | 25.83 | 24.86 | 3.04 | 1.51 | 1.16 | 17.44 | 0.1628 | 0.00 | 4.65 | 6.47 | 59.10 | 62.32 | 20.92 | -- |
| KPC Pharmaceuticals Inc | 7.70bn | 530.05m | 9.31bn | 5.28k | 17.41 | 1.75 | -- | 1.21 | 0.7067 | 0.7067 | 10.21 | 7.01 | 0.6987 | 2.98 | 2.48 | 1,458,805.00 | 6.21 | 5.65 | 11.19 | 9.98 | 41.77 | 43.07 | 8.89 | 6.71 | 1.58 | -- | 0.1981 | 34.63 | -0.3408 | 0.6839 | 19.86 | 7.36 | -25.55 | 8.45 |
| North China Pharmaceutical Co Ltd | 9.79bn | 183.03m | 9.44bn | 10.09k | 51.65 | 1.71 | -- | 0.9635 | 0.1065 | 0.1065 | 5.69 | 3.21 | 0.453 | 2.91 | 4.26 | 970,873.20 | 1.30 | -0.2469 | 3.23 | -0.578 | 30.05 | 33.78 | 2.86 | -0.5243 | 0.4902 | 2.22 | 0.6254 | -- | -2.48 | -2.94 | 2,496.80 | -5.90 | 3.21 | 0.00 |
| Youcare Pharmaceutical Group Co Ltd | 2.55bn | -233.99m | 9.49bn | 3.28k | -- | 2.77 | -- | 3.72 | -0.5306 | -0.5306 | 5.75 | 7.62 | 0.4537 | 2.18 | 4.03 | 777,123.10 | -4.30 | 5.90 | -5.97 | 8.92 | 47.55 | 63.64 | -9.48 | 7.49 | 1.49 | -41.24 | 0.1633 | 66.99 | -9.90 | -2.48 | -33.05 | -15.40 | 19.36 | -- |
| Shandong Lukang Pharmaceutical Co Ltd | 6.19bn | 188.75m | 9.53bn | 6.39k | 43.65 | 2.07 | -- | 1.54 | 0.2089 | 0.2089 | 6.85 | 4.40 | 0.6891 | 3.69 | 6.77 | 969,079.80 | 2.20 | 2.78 | 3.60 | 5.00 | 22.98 | 22.76 | 3.20 | 4.17 | 0.7984 | 6.01 | 0.4324 | 31.07 | 1.41 | 10.80 | 60.30 | 26.62 | -19.55 | 24.01 |
| Chongqing Taiji Industry Group Co Ltd | 10.04bn | -352.52m | 9.69bn | 11.97k | -- | 2.74 | -- | 0.965 | -0.8238 | -0.8238 | 18.98 | 6.42 | 0.7032 | 2.85 | 3.55 | 838,688.20 | -2.36 | 0.9924 | -6.94 | 3.04 | 26.30 | 43.37 | -3.35 | 1.08 | 0.4906 | 0.5756 | 0.5914 | 22.39 | -20.72 | 1.24 | -96.76 | -- | -3.36 | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 7.92m | 0.49% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 4.73m | 0.29% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.30m | 0.26% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.87m | 0.24% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025 | 2.82m | 0.17% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 2.33m | 0.14% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 1.57m | 0.10% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 1.05m | 0.06% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 523.60k | 0.03% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 291.40k | 0.02% |
